Akari Therapeutics Plc
About Akari Therapeutics Plc
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $367.9K
- Net income
- -$17.3M
- Total assets
- $47.9M
- Market cap
- $17.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $17.3M
- Operating income
- -$17.3M
- Net income
- -$17.3M
- EPS (basic)
- $0.00
- EPS (diluted)
- $0.00
Balance sheet
- Total assets
- $47.9M
- Current assets
- $5.5M
- Total liabilities
- $19.6M
- Current liabilities
- $12.4M
- Shareholders’ equity
- $28.3M
Cash flow
- Operating cash flow
- -$10.6M
- Investing cash flow
- -$2.6M
- Financing cash flow
- $13.2M
- Net cash flow
- -$1.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $17.2M
- Shares outstanding
- 1.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 7, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $17.3M in FY2023.
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Akari Therapeutics Plc.
Write a review
News about Akari Therapeutics Plc
News & sentiment via Polygon.io
